Wedbush Maintains Neutral on Cognyte Software, Lowers Price Target to $9
Wedbush analyst Daniel Ives maintains Cognyte Software (NASDAQ:CGNT) with a Neutral and lowers the price target from $17 to $9.
51 Biggest Movers From Yesterday
Gainers
Sunshine Biopharma, Inc. (NASDAQ: SBFM) shares surged 148.2% to close at $5.61 on Tuesday after the company announced that two of its designed mRNA molecules are effective at destroying cancer cells grown in culture.
Mid-Afternoon Market Update: Dow Falls 150 Points; Cognyte Software Shares Drop
U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping more than 150 points on Tuesday.
Mid-Day Market Update: Dow Dips Over 100 Points; Sunshine Biopharma Shares Surge
U.S. stocks traded lower midway through trading, with the Dow Jones dropping more than 100 points on Tuesday.
Mid-Morning Market Update: Markets Mixed; ISM Services PMI Rises To 58.3 In March
U.S. stocks traded mixed this morning, with the Nasdaq Composite dropping around 150 points on Tuesday.
Earnings Scheduled For April 5, 2022
Companies Reporting Before The Bell
• Acuity Brands (NYSE:AYI) is projected to report quarterly earnings at $2.37 per share on revenue of $884.62 million.
75 Biggest Movers From Yesterday
Gainers
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) shares jumped 299.4% to close at $6.23 on Monday as the company received clearance from the FDA to initiate a pharmacokinetic study of PrimeC in healthy adult subjects.
Where Cognyte Software Stands With Analysts
Cognyte Software (NASDAQ:CGNT) has observed the following analyst ratings within the last quarter:
Stocks That Hit 52-Week Lows On Thursday
During Thursday's morning trading, 152 companies set new 52-week lows.